

SUPPLEMENTARY FIGURES




Distribution of Confounders in Training Cohort


Figure S1. Differences in cohort characteristics between healthy volunteers (HV) and MS patients. Distribution of five continuous confounders is shown as histograms with HV cohort in black and MS cohort in while colors. The proportions and absolute numbers of males and females in HV and MS cohorts are displayed as a bar chart with females show in pink and males in blue. There are no significant differences between HV and MS cohort in all confounders except age (and age^2).

Grey Matter Volumes













Adjusted = measured + 806.43*BMI - 20.37*Age² - 104390.2*Height + 419.62*Intracranial volume + 179879.28





D











Figure S2. Grey matter volumes with residual variance with age within training cohort.


Left panels all show unadjusted grey matter volumes while right panels show confounderadjusted grey matter volumes. Red line and points indicate HV cohort while blue line and points indicate MS cohort. Adjustment equations respective to MRI feature are shown on top of the plot showing adjusted MRI volumes.

White Matter Volumes



Diagnosis - HV - MS - Non-MS

Figure S3. Left panels all show unadjusted white matter volumes while right panels show confounder-adjusted white matter volumes. Red line and points indicate HV cohort while blue line and points indicate MS cohort. Adjustment equations respective to MRI feature are shown on top of the plot showing adjusted MRI volumes.



Thalamic and Ventricular CSF Volumes

Figure S4. Left panels all show unadjusted thalamic and ventricular CSF volumes while right panels show confounder-adjusted volumes. Red line and points indicate HV cohort while blue line and points indicate MS cohort. Adjustment equations respective to MRI feature are shown on top of the plot showing adjusted MRI volumes.

Brain Parenchymal Fraction Adjustment




Figure S5. Adjustment of single MRI biomarker (i.e., brain parenchymal fraction) for six physiological confounders. A. The final equation for the confounder-adjusted brain parenchymal fraction is shown at the top in red outline. This equation was derived from multiple linear regression models as described in the Method section. **B.** In the top right corner is resulting radar chart that show proportional weights of the applied confounder adjustment, with confounders with lowest weights (i.e., the innermost circle) representing zeros. **C.** Univariate linear regression models between each tested confounder on x-axis (first 5 graphs) or gender

(sixth graph) and measured brain parenchymal fraction on the y-axis in 80 healthy volunteers (HV). **D.** Same univariate regressions in the HV cohort after applying adjustment formula show no remaining effect of confounders. **E.** Applying HV-derived adjustment formula to MS cohort shows no residual effect.

Brainstem Adjustment




Figure S6. Adjustment of single MRI biomarker (i.e., brainstem volume) for six

physiological confounders. A. The final equation for the confounder-adjusted brainstem volume is shown at the top in red outline. This equation was derived from multiple linear regression models as described in the Method section. **B.** In the top right corner is resulting radar chart that show proportional weights of the applied confounder adjustment, with confounders with lowest weights (i.e., the innermost circle) representing zeros. **C.** Univariate linear regression models between each tested confounder on x-axis (first 5 graphs) or gender (sixth graph) and measured

brainstem volume on the y-axis in 80 healthy volunteers (HV). **D.** Same univariate regressions in the HV cohort after applying adjustment formula show no remaining effect of confounders. **E.** Applying HV-derived adjustment formula to MS cohort resulted in no residual effect.

Caudate Adjustment





Figure S7. Adjustment of single MRI biomarker (i.e., caudate volume) for six physiological confounders. A. The final equation for the confounder-adjusted caudate volume is shown at the top in red outline. This equation was derived from multiple linear regression models as described in the Method section. **B.** In the top right corner is resulting radar chart that show proportional weights of the applied confounder adjustment, with confounders with lowest weights (i.e., the innermost circle) representing zeros. **C.** Univariate linear regression models between each tested confounder on x-axis (first 5 graphs) or gender (sixth graph) and measured caudate volume on

the y-axis in 80 healthy volunteers (HV). **D.** Same univariate regressions in the HV cohort after applying adjustment formula show no remaining effect of confounders. **E.** Applying HV-derived adjustment formula to MS cohort shows residual effect of age and age^2, when considering Bonferroni adjustment for multiple comparisons (i.e., p<0.05/12 = p<0.004).



Cerebellum GM Adjustment

Figure S8. Adjustment of single MRI biomarker (i.e., cerebellum GM volume) for six physiological confounders. A. The final equation for the confounder-adjusted cerebellum GM volume is shown at the top in red outline. This equation was derived from multiple linear

regression models as described in the Method section. **B.** In the top right corner is resulting radar chart that show proportional weights of the applied confounder adjustment, with confounders with lowest weights (i.e., the innermost circle) representing zeros. **C.** Univariate linear regression models between each tested confounder on x-axis (first 5 graphs) or gender (sixth graph) and measured cerebellum GM volume on the y-axis in 80 healthy volunteers (HV). **D.** Same univariate regressions in the HV cohort after applying adjustment formula show no remaining effect of confounders. **E.** Applying HV-derived adjustment formula to MS cohort resulted in no residual effect.

Cerebellum WM Adjustment




Figure S9. Adjustment of single MRI biomarker (i.e., cerebellum WM volume) for six physiological confounders. A. The final equation for the confounder-adjusted cerebellum WM volume is shown at the top in red outline. This equation was derived from multiple linear regression models as described in the Method section. **B.** In the top right corner is resulting radar chart that show proportional weights of the applied confounder adjustment, with confounders with lowest weights (i.e., the innermost circle) representing zeros. **C.** Univariate linear regression models between each tested confounder on x-axis (first 5 graphs) or gender (sixth graph) and

measured cerebellum WM volume on the y-axis in 80 healthy volunteers (HV). **D.** Same univariate regressions in the HV cohort after applying adjustment formula show no remaining effect of confounders. **E.** Applying HV-derived adjustment formula to MS cohort resulted in no residual effect.

Cerebrum GM Adjustment




Figure S10. Adjustment of single MRI biomarker (i.e., cerebrum GM volume) for six physiological confounders. A. The final equation for the confounder-adjusted cerebrum GM volume is shown at the top in red outline. This equation was derived from multiple linear regression models as described in the Method section. **B.** In the top right corner is resulting radar chart that show proportional weights of the applied confounder adjustment, with confounders with lowest weights (i.e., the innermost circle) representing zeros. **C.** Univariate linear regression models between each tested confounder on x-axis (first 5 graphs) or gender (sixth graph) and

measured cerebrum GM volume on the y-axis in 80 healthy volunteers (HV). **D.** Same univariate regressions in the HV cohort after applying adjustment formula show no remaining effect of confounders. **E.** Applying HV-derived adjustment formula to MS cohort shows residual effect of age and age^2 when considering Bonferroni adjustment for multiple comparisons (i.e., p<0.05/12 = p<0.004).

Normal Appearing WM Adjustment




Figure S11. Adjustment of single MRI biomarker (i.e., normal-appearing WM volume) for six physiological confounders. A. The final equation for the confounder-adjusted normalappearing WM volume is shown at the top in red outline. This equation was derived from multiple linear regression models as described in the Method section. **B.** In the top right corner is resulting radar chart that show proportional weights of the applied confounder adjustment, with confounders with lowest weights (i.e., the innermost circle) representing zeros. **C.** Univariate linear regression models between each tested confounder on x-axis (first 5 graphs) or gender (sixth graph) and measured normal-appearing WM volume on the y-axis in 80 healthy volunteers (HV). **D.** Same univariate regressions in the HV cohort after applying adjustment formula show no remaining effect of confounders. **E.** Applying HV-derived adjustment formula to MS cohort shows residual effect of age and age^2.

Putamen Adjustment




Figure S12. Adjustment of single MRI biomarker (i.e., putamen volume) for six

physiological confounders. A. The final equation for the confounder-adjusted putamen volume is shown at the top in red outline. This equation was derived from multiple linear regression models as described in the Method section. **B.** In the top right corner is resulting radar chart that show proportional weights of the applied confounder adjustment, with confounders with lowest weights (i.e., the innermost circle) representing zeros. **C.** Univariate linear regression models between each tested confounder on x-axis (first 5 graphs) or gender (sixth graph) and measured

putamen volume on the y-axis in 80 healthy volunteers (HV). **D.** Same univariate regressions in the HV cohort after applying adjustment formula show no remaining effect of confounders. **E.** Applying HV-derived adjustment formula to MS cohort shows residual effect of age and age^2, when considering Bonferroni adjustment for multiple comparisons (i.e., p<0.05/12 = p<0.004).

Spinal Cord Adjustment




Figure S13. Adjustment of single MRI biomarker (i.e., spinal cord average cross section area) for six physiological confounders. A. The final equation for the confounder-adjusted spinal cord cross section area (CSA) is shown at the top in red outline. This equation was derived from multiple linear regression models as described in the Method section. **B.** In the top right corner is resulting radar chart that show proportional weights of the applied confounder adjustment, with confounders with lowest weights (i.e., the innermost circle) representing zeros. **C.** Univariate linear regression models between each tested confounder on x-axis (first 5 graphs) or gender (sixth graph) and measured spinal cord CSA on the y-axis in 80 healthy volunteers (HV). **D.** Same univariate regressions in the HV cohort after applying adjustment formula show no remaining effect of confounders. **E.** Applying HV-derived adjustment formula to MS cohort resulted in no residual effect.

Sulcal CSF Adjustment




Figure S14. Adjustment of single MRI biomarker (i.e., sulcal CSF volume) for six physiological confounders. A. The final equation for the confounder-adjusted sulcal CSF volume is shown at the top in red outline. This equation was derived from multiple linear regression models as described in the Method section. **B.** In the top right corner is resulting radar chart that show proportional weights of the applied confounder adjustment, with confounders with lowest weights (i.e., the innermost circle) representing zeros. **C.** Univariate linear regression models between each tested confounder on x-axis (first 5 graphs) or gender (sixth graph) and

measured sulcal CSF volume on the y-axis in 80 healthy volunteers (HV). **D.** Same univariate regressions in the HV cohort after applying adjustment formula show no remaining effect of confounders. **E.** Applying HV-derived adjustment formula to MS cohort shows residual effect of intracranial volume.

Supratentorial GM Adjustment




Figure S15. Adjustment of single MRI biomarker (i.e., supratentorial GM volume) for six physiological confounders. A. The final equation for the confounder-adjusted supratentorial GM volume is shown at the top in red outline. This equation was derived from multiple linear regression models as described in the Method section. **B.** In the top right corner is resulting radar chart that show proportional weights of the applied confounder adjustment, with confounders with lowest weights (i.e., the innermost circle) representing zeros. **C.** Univariate linear regression models between each tested confounder on x-axis (first 5 graphs) or gender (sixth graph) and

measured supratentorial GM volume on the y-axis in 80 healthy volunteers (HV). **D.** Same univariate regressions in the HV cohort after applying adjustment formula show no remaining effect of confounders. **E.** Applying HV-derived adjustment formula to MS cohort shows residual effect of age and age^2.

Supratentorial WM Adjustment




Figure S16. Adjustment of single MRI biomarker (i.e., supratentorial WM volume) for six physiological confounders. A. The final equation for the confounder-adjusted supratentorial WM volume is shown at the top in red outline. This equation was derived from multiple linear regression models as described in the Method section. **B.** In the top right corner is resulting radar chart that show proportional weights of the applied confounder adjustment, with confounders with lowest weights (i.e., the innermost circle) representing zeros. **C.** Univariate linear regression models between each tested confounder on x-axis (first 5 graphs) or gender (sixth graph) and

measured supratentorial WM volume on the y-axis in 80 healthy volunteers (HV). **D.** Same univariate regressions in the HV cohort after applying adjustment formula show no remaining residual effect of confounders. **E.** Applying HV-derived adjustment formula to MS cohort shows residual effect of age and age^2.

Thalamus Adjustment




Figure S17. Adjustment of single MRI biomarker (i.e., thalamus volume) for six

physiological confounders. A. The final equation for the confounder-adjusted thalamus volume is shown at the top in red outline. This equation was derived from multiple linear regression models as described in the Method section. **B.** In the top right corner is resulting radar chart that show proportional weights of the applied confounder adjustment, with confounders with lowest weights (i.e., the innermost circle) representing zeros. **C.** Univariate linear regression models between each tested confounder on x-axis (first 5 graphs) or gender (sixth graph) and measured

thalamus volume on the y-axis in 80 healthy volunteers (HV). **D.** Same univariate regressions in the HV cohort after applying adjustment formula show no remaining residual effect of confounders. **E.** Applying HV-derived adjustment formula to MS cohort shows no residual effect, when considering Bonferroni adjustment for multiple comparisons (i.e., p<0.05/12 = p<0.004).

Lesion Volume Adjustment




Figure S18. Adjustment of single MRI biomarker (i.e., lesion volume) for six physiological confounders. A. No confounder-adjustment was made for lesion volume. Possible adjustment was derived from multiple linear regression models as described in the Method section. B. In the top right corner is resulting radar chart that show proportional weights of the applied confounder adjustment, with confounders with lowest weights (i.e., the innermost circle) representing zeros.
C. Univariate linear regression models between each tested confounder on x-axis (first 5 graphs) or gender (sixth graph) and measured lesion volume on the y-axis in 80 healthy volunteers (HV).

D. No univariate linear regression of confounders was seen in the HV cohort. **E.** No univariate linear regression of confounders was seen in the MS cohort.

	Scale	Feature	R Squared	Rho	p-value		Scale	Feature	R Squared	Rho	p-value
	CombiWISE	Age	0.211	0.440	1.18E-12			Age	0.211	0.440	1.18E-12
		Spinal Cord	0.161	-0.407	2.71E-10			Spinal Cord	0.063	-0.254	1.22E-04
		Ventricular CSF	0.104	0.338	1.27E-07			Ventricular CSF	0.068	0.278	1.67E-05
		Sulcal CSF	0.021	0.143	2.77E-02		CombiWISE	Sulcal CSF	0.000	0.013	8.46E-01
		Cerebellum WM	0.041	-0.259	6.44E-05			Cerebellum WM	0.016	-0.147	2.46E-02
		Supratentorial WM	0.027	-0.152	2.02E-02			Supratentorial WM	0.047	-0.203	1.90E-03
		Normal-appearing WM	0.088	-0.255	7.66E-05			Normal-appearing WM	0.130	-0.304	2.03E-06
		Thalamus	0.125	-0.380	1.67E-09			Thalamus	0.006	-0.094	1.49E-01
		Caudate	0.045	-0.231	3.43E-04			Caudate	0.003	-0.059	3.67E-01
		Brain Parenchymal Fraction	0.097	-0.300	2.55E-06			Brain Parenchymal Fraction	0.008	-0.087	1.80E-01
		Lesion Volume	0.028	0.346	4.75E-08			Lesion Volume	0.028	0.346	4.75E-08
		Age	0.241	0.443	8.69E-13		EDSS	Age	0.241	0.443	8.69E-13
		Spinal Cord	0.160	-0.408	2.48E-10			Spinal Cord	0.057	-0.264	6.77E-05
		Ventricular CSF	0.081	0.291	6.19E-06			Ventricular CSF	0.045	0.223	6.08E-04
		Sulcal CSF	0.012	0.112	8.54E-02			Sulcal CSF	0.001	-0.042	5.21E-01
	EDSS	Cerebellum WM	0.034	-0.226	4.98E-04			Cerebellum WM	0.010	-0.119	7.08E-02
		Supratentorial WM	0.025	-0.121	6.69E-02			Supratentorial WM	0.039	-0.163	1.27E-02
		Normal-appearing WM	0.073	-0.213	1.04E-03			Normal-appearing WM	0.102	-0.249	1.17E-04
D		Thalamus	0.109	-0.321	4.76E-07	_		Thalamus	0.001	-0.036	5.79E-01
Unadjusted		Caudate	0.041	-0.183	4.72E-03	l Da		Caudate	0.001	-0.011	8.72E-01
		Brain Parenchymal Fraction	0.071	-0.242	1.68E-04			Brain Parenchymal Fraction	0.001	-0.018	7.81E-01
		Lesion Volume	0.018	0.280	1.25E-05	n si		Lesion Volume	0.018	0.280	1.25E-05
	NeurEx	Age	0.194	0.470	2.00E-14	-		Age	0.194	0.470	2.00E-14
		Spinal Cord	0.145	-0.404	3.73E-10	A		Spinal Cord	0.056	-0.240	3.06E-04
		Ventricular CSF	0.090	0.327	3.30E-07			Ventricular CSF	0.060	0.260	5.93E-05
		Sulcal CSF	0.014	0.121	6.30E-02			Sulcal CSF	0.001	0.008	9.07E-01
		Cerebellum WM	0.067	-0.296	4.12E-06			Cerebellum WM	0.028	-0.169	9.64E-03
		Supratentorial WM	0.048	-0.224	5.93E-04			Supratentorial WM	0.064	-0.270	3.16E-05
		Normal-appearing WM	0.099	-0.310	1.26E-06			Normal-appearing WM	0.121	-0.352	2.94E-08
		Thalamus	0.149	-0.414	3.43E-11			Thalamus	0.014	-0.111	8.83E-02
		Caudate	0.062	-0.265	3.60E-05			Caudate	0.007	-0.074	2.60E-01
		Brain Parenchymal Fraction	0.090	-0.301	2.29E-06			Brain Parenchymal Fraction	0.011	-0.085	1.93E-01
		Lesion Volume	0.036	0.337	1.07E-07			Lesion Volume	0.036	0.337	1.07E-07
	SDMT	Age	0.123	-0.368	5.19E-09			Age	0.123	-0.368	5.19E-09
		Spinal Cord	0.030	0.196	3.17E-03			Spinal Cord	0.003	0.073	2.80E-01
		Ventricular CSF	0.220	-0.495	9.90E-16			Ventricular CSF	0.194	-0.476	1.64E-14
		Sulcal CSF	0.071	-0.261	4.85E-05			Sulcal CSF	0.038	-0.195	2.58E-03
		Cerebellum WM	0.059	0.301	2.93E-06			Cerebellum WM	0.039	0.238	2.47E-04
		Supratentorial WM	0.028	0.192	3.12E-03		SDMT	Supratentorial WM	0.074	0.289	6.76E-06
		Normal-appearing WM	0.063	0.282	1.12E-05			Normal-appearing WM	0.120	0.385	9.00E-10
		Thalamus	0.263	0.549	5.92E-20			Thalamus	0.101	0.311	1.14E-06
		Caudate	0.198	0.465	4.02E-14			Caudate	0.107	0.335	1.26E-07
		Brain Parenchymal Fraction	0.217	0.468	2.66E-14			Brain Parenchymal Fraction	0.093	0.296	3.56E-06
		Lesion Volume	0.142	-0.493	6.27E-16			Lesion Volume	0.142	-0.493	6.27E-16

Supplementary Table S1. Unilateral correlations of disability outcomes with MRI features.

The left panel shows R squared, Spearman correlation coefficients (Rho), and p-values between unadjusted MRI features and disability outcomes. The right panel shows R squared, Spearman correlation coefficients, and p-values between confounder-adjusted MRI features and disability outcomes.

Scale	Cohort	Model	RMSE	R Squared	Rho	CCC	p-value
	Troining	Unadjusted	10.10	0.74	0.86	0.76	2.30E-63
	Training	Adjusted	10.79	0.70	0.83	0.71	2.13E-54
CombiWISE	Training (Cross Validation)	Unadjusted	14.11	0.31	0.58	0.47	4.97E-03
CombiWISE	Training (Cross Validation)	Adjusted	14.89	0.33	0.54	0.43	1.15E-02
	Validation	Unadjusted	17.57	0.21	0.48	0.34	2.56E-08
	validation	Adjusted	17.01	0.26	0.52	0.35	1.89E-09
	Troining	Unadjusted	1.20	0.71	0.80	0.72	9.83E-49
	Training	Adjusted	1.21	0.69	0.78	0.71	3.84E-43
EDSS	Training (Cross Validation)	Unadjusted	1.71	0.33	0.48	0.44	2.62E-02
ED35	Training (Cross Valuation)	Adjusted	1.67	0.29	0.50	0.45	2.08E-02
	Validation	Unadjusted	1.84	0.18	0.47	0.31	5.93E-08
	valuation	Adjusted	1.75	0.26	0.49	0.39	2.49E-08
	Training	Unadjusted	50.69	0.69	0.84	0.73	1.83E-56
	Training	Adjusted	51.60	0.69	0.84	0.72	2.93E-56
NeurEx	Training (Cross Validation)	Unadjusted	71.47	0.36	0.58	0.49	6.35E-03
Neurex	Training (Cross Valuation)	Adjusted	69.98	0.32	0.58	0.46	5.54E-03
	Validation	Unadjusted	86.49	0.20	0.47	0.35	8.92E-08
	validation	Adjusted	83.02	0.26	0.54	0.38	3.58E-10
	Training	Unadjusted	8.53	0.69	0.84	0.72	9.49E-59
	Training	Adjusted	7.26	0.78	0.89	0.81	7.38E-75
SDMT	Training (Cross Validation)	Unadjusted	10.98	0.33	0.61	0.46	3.76E-03
SUWIT	Training (Cross Validation)	Adjusted	10.43	0.40	0.66	0.51	1.18E-03
	Validation	Unadjusted	12.26	0.33	0.57	0.47	2.23E-11
	valuation	Adjusted	12.16	0.34	0.57	0.49	2.93E-11

Supplementary Table S2. Statistics on model performances in each cohort.

This table shows model performances in predicting disability scales individually within the

training cohort, training cohort with cross validation, and independent validation cohort.